Source:http://linkedlifedata.com/resource/pubmed/id/12684679
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2003-4-9
|
| pubmed:abstractText |
P-glycoprotein, encoded by the MDR-1 gene, confers multi-drug resistance against antineoplastic agents and is important for the transmembrane transition of various other common therapeutic drugs. Recently, a number of polymorphisms in the MDR-1 gene were identified and the T/T genotype at position 3435 in exon 26 was found to correlate with intestinal P-glycoprotein expression and bioavailability of digoxin after oral administration. We analysed the allelic frequencies at the polymorphic site C3435T in a group of patients with locally advanced breast cancer treated by preoperative chemotherapy to evaluate its predictive value. Sixty-eight patients diagnosed between 1998 and 2001 were treated by preoperative chemotherapy with anthracyclines or these agents combined with taxanes. From genomic DNA, a 106 bp fragment of MDR-1 exon 26 was amplified and the C3435T genotype was determined by Pyrosequencing methodology. A potential correlation with therapeutic response was calculated with Fisher's exact test. The overall clinical response rate (cCR and cPR) was 68% but only 7 patients (10.3%) achieved pathological complete response (pCR). Heterozygous C3435T occurred in 57% of the subjects and 22% of the analysed individuals possessed only T alleles. Statistical analysis revealed a significant correlation (p=0.029) between clinical complete response to preoperative chemotherapy and the T/T genotype. MDR-1 polymorphism C3435T in exon 26 may co-determine resistance to chemotherapy and provide useful information to individualize therapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Digoxin,
http://linkedlifedata.com/resource/pubmed/chemical/P-Glycoprotein,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1019-6439
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
22
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1117-21
|
| pubmed:dateRevised |
2006-4-24
|
| pubmed:meshHeading |
pubmed-meshheading:12684679-Administration, Oral,
pubmed-meshheading:12684679-Aged,
pubmed-meshheading:12684679-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12684679-Biological Availability,
pubmed-meshheading:12684679-Breast Neoplasms,
pubmed-meshheading:12684679-Chemotherapy, Adjuvant,
pubmed-meshheading:12684679-Digoxin,
pubmed-meshheading:12684679-Exons,
pubmed-meshheading:12684679-Female,
pubmed-meshheading:12684679-Genes, MDR,
pubmed-meshheading:12684679-Genotype,
pubmed-meshheading:12684679-Humans,
pubmed-meshheading:12684679-Lymphatic Metastasis,
pubmed-meshheading:12684679-Menopause,
pubmed-meshheading:12684679-Middle Aged,
pubmed-meshheading:12684679-P-Glycoprotein,
pubmed-meshheading:12684679-Polymorphism, Single Nucleotide,
pubmed-meshheading:12684679-Predictive Value of Tests,
pubmed-meshheading:12684679-Receptors, Estrogen,
pubmed-meshheading:12684679-Receptors, Progesterone,
pubmed-meshheading:12684679-Treatment Outcome,
pubmed-meshheading:12684679-Tumor Suppressor Protein p53
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer.
|
| pubmed:affiliation |
Department of Obstetrics and Gynecology, University of Ulm Medical School, Ulm, Germany.
|
| pubmed:publicationType |
Journal Article
|